AMGN vs MRNA vs VRTX Stock Comparison

Amgen, Moderna and Vertex Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$253.65B
P/E
27.0x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
5 wins
MRNA Moderna, Inc.
$223.37 -1.3% 1M +794.9% 1Y
Market cap
$87.38B
P/E
–
Revenue (TTM)
$2.53B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

11 decided of 12

Amgen leads on 5 of the 12 questions below (Amgen 5, Vertex Pharmaceuticals 4, Moderna 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMGNMRNAVRTXLeader
Larger companyMarket capitalisation $253.65B $87.38B $137.06B AMGN
Cheaper on earningsLower P/E, profitable companies only 27.0x -31.3x 34.5x AMGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 20.9x — 30.4x AMGN
Faster revenue growthRevenue growth, trailing twelve months +8.2% +13.1% +10.5% MRNA
More profitableNet margin, trailing twelve months 24.1% -110.5% 30.7% VRTX
Better return on capitalReturn on invested capital 15.6% -39.6% — AMGN
Less leveragedLower net debt / EBITDA 2.4x 1.7x -0.4x VRTX
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +38.6% +794.9% +24.0% MRNA
Better 5-year returnAnnualised price return, 5 years +17.1%/yr -0.7%/yr +23.5%/yr VRTX
Less volatileAnnualised volatility, 1 year 28.8% 130.6% 29.5% AMGN
Higher overall scoreMean of the five percentile scores vs peers 66/100 60/100 73/100 VRTX

Percentile Scorecard

AMGNMRNAVRTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMGNMRNAVRTX
Valuation 85 #103 of 660 69 #208 of 660 77 #152 of 660
Growth 61 #245 of 619 45 #344 of 619 46 #333 of 619
Profitability 95 #32 of 595 60 #239 of 595 93 #40 of 595
Financial Health 23 #528 of 683 52 #330 of 683 55 #311 of 683
Shareholder Returns 67 #152 of 459 76 #112 of 459 92 #37 of 459
Overall 66 60 73
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRNA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VRTX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMGNMRNAVRTXSPY
1 month +9.3%-1.3%+8.0% -2.0%
3 months +12.2%+252.8%+6.5% -2.8%
6 months +42.7%+355.5%+23.3% +2.0%
Year to date +42.3%+657.4%+18.8% +10.6%
1 year +38.6%+794.9%+24.0% +12.2%
3 years +72.5%+201.4%+45.6% +68.1%
3 years, per year +19.9%+44.5%+13.3% +18.9%
5 years +120.3%-3.4%+187.6% +61.4%
5 years, per year +17.1%-0.7%+23.5% +10.1%
10 years +212.4%—+485.4% +248.5%
10 years, per year +12.1%—+19.3% +13.3%

Risk

MeasureAMGNMRNAVRTXSPY
Volatility, 1Y 28.8%130.6%29.5% 13.6%
Downside volatility, 1Y 28.4%79.2%26.1% 13.9%
Beta vs S&P 500, 1Y 0.492.260.43 1.00
Return / volatility, 1Y 1.346.090.81 0.90
Max drawdown, 5Y -26.7%-93.9%-29.1% -25.4%
From 52-week high -2.7%-16.9%-3.6% -3.2%
52-week high $478.48$268.86$558.71 $779.14
52-week low $313.85$22.36$421.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMGNMRNAVRTX
P/E now vs peer median 26.8xmedian 17.0x -32.1xmedian 17.0x 34.3xmedian 17.0x
P/S now vs peer median 6.5xmedian 8.4x 35.7xmedian 8.4x 10.5xmedian 8.4x
EV/EBITDA now vs peer median 17.1xmedian 14.6x -32.0xmedian 14.6x 29.7xmedian 14.6x
P/FCF now vs peer median 26.3xmedian 19.0x -45.8xmedian 19.0x 42.6xmedian 19.0x
P/B now vs peer median 17.6xmedian 2.0x 13.2xmedian 2.0x 6.5xmedian 2.0x
PEG now vs peer median 3.86median 0.43 -3.01median 0.43 6.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMGNMRNAVRTX
Revenue $38.90B $2.53B $12.95B
Gross profit $27.58B $707.00M $11.08B
Operating income $12.61B -$2.93B $4.30B
Net income $9.39B -$2.79B $3.98B
Free cash flow $9.58B -$1.97B $3.20B
R&D $7.84B $2.66B $4.25B
EPS (diluted) $17.20 $-6.49 $15.58
Cash & equivalents $13.19B $1.20B $4.98B
Total debt $54.01B $591.00M $4.50B
Shares (diluted) 546.00M 430.00M 255.20M
Enterprise value $205.30B $66.06B $104.79B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMGNMRNAVRTX
P/E 26.8x -32.1x 34.3x
P/FCF 26.3x -45.8x 42.6x
P/Operating cash flow 20.9x -50.6x 37.0x
P/S 6.5x 35.7x 10.5x
P/B 17.6x 13.2x 6.5x
P/Tangible book -48.6x 13.2x 11.0x
EV/EBITDA 17.1x -32.0x 29.7x
EV/EBIT 23.2x -29.2x 31.3x
EV/Revenue 7.5x 33.9x 10.4x
EV/FCF 30.5x -43.5x 42.1x
EV/Operating cash flow 24.3x -48.0x 36.5x
PEG (3Y EPS CAGR) 3.86 -3.01 6.39

Growth

14 metrics
MetricAMGNMRNAVRTX
Revenue growth (1Y) 8.2% 13.1% 10.5%
Revenue CAGR (3Y) 13.2% -34.8% 10.3%
Gross profit growth (1Y) 15.9% -34.4% 9.5%
Gross profit CAGR (3Y) 11.8% -41.0% 9.3%
Operating income growth (1Y) 45.4% 15.4% 7.8%
Operating income CAGR (3Y) 12.5% -3.2% 3.5%
Net income growth (1Y) 34.1% 10.5% 8.2%
Net income CAGR (3Y) 7.5% 7.0% 4.6%
EPS growth (1Y) 33.1% 18.8% 9.2%
EPS CAGR (3Y) 6.9% 10.7% 5.4%
Operating cash flow growth (1Y) -8.3% 9.8% -0.6%
Operating cash flow CAGR (3Y) 4.4% 4.9% -5.5%
Free cash flow growth (1Y) -17.0% 25.7% -4.0%
Free cash flow CAGR (3Y) 0.7% 9.5% -8.7%

Profitability

14 metrics
MetricAMGNMRNAVRTX
Gross margin 70.9% 28.0% 85.5%
EBITDA margin 43.9% -105.9% 35.1%
Operating margin 32.4% -116.0% 33.2%
Pretax margin 28.4% -108.1% 36.7%
Net margin 24.1% -110.5% 30.7%
FCF margin 24.6% -78.0% 24.7%
Operating cash flow margin 30.9% -70.7% 28.5%
Return on equity 72.1% -41.0% 19.3%
Return on assets 9.8% -22.8% 13.2%
Return on invested capital 15.6% -39.6% –
Return on capital employed 17.4% -28.8% 17.2%
Asset turnover 0.4x 0.2x 0.4x
Cash conversion (OCF / net income) 1.3x 0.6x 0.9x
Stock comp / revenue 1.3% 18.4% 5.2%

Financial Health

11 metrics
MetricAMGNMRNAVRTX
Debt / assets 56.2% 4.4% 13.7%
Debt / equity 3.8x 0.1x 0.2x
Net debt / EBITDA 2.4x 1.7x -0.4x
Debt / FCF 5.6x -0.3x 1.4x
Liabilities / assets 85.1% 49.2% 36.1%
Equity / assets 14.9% 50.8% 63.9%
Interest coverage 4.8x – 93.0x
Current ratio 1.5x 3.6x 2.3x
Quick ratio 1.0x 3.2x 1.7x
Cash ratio 0.6x 2.5x 1.3x
Altman Z-score 2.54 8.66 8.70

Shareholder Returns

7 metrics
MetricAMGNMRNAVRTX
Dividend yield 2.1% – –
Net buyback yield – -0.2% 0.7%
Shareholder yield 2.1% -0.2% 0.7%
Payout ratio (earnings) 57.1% – –
Payout ratio (FCF) 56.0% – –
Dividend growth (1Y) 6.3% – –
Dividend CAGR (3Y) 6.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMGNMRNAVRTX
Forward P/E 20.9xFY2026 – 30.4xFY2026
EPS, next fiscal year $22.28FY2026 $-7.17FY2026 $17.71FY2026
EPS growth, next FY +2.0%FY2026 – -3.7%FY2026
EPS growth, the year after +7.2% – +20.2%
Revenue, next fiscal year $42.01BFY2026 $2.22BFY2026 $12.68BFY2026
Revenue growth, next FY +14.3%FY2026 +14.6%FY2026 +5.9%FY2026
Revenue growth, the year after +3.1% +25.8% +19.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMGNMRNAVRTX
Held by institutions 82.7% 80.2% 95.1%
Institutions holding 3,163 787 1,747
Change in shares held, QoQ +4.5% +3.4% +3.9%
Institutions buying 1,452 404 904
Institutions selling 1,219 239 605
Buyers to sellers 1.19 1.69 1.49

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMGNMRNAVRTX
AMGN 1.00 0.27 0.59
MRNA 0.27 1.00 0.34
VRTX 0.59 0.34 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMGN, MRNA and VRTX?

Amgen (AMGN) is the largest by market capitalisation: Amgen (AMGN) $253.65B, Moderna (MRNA) $87.38B, Vertex Pharmaceuticals (VRTX) $137.06B.

Which stock is cheaper, AMGN, MRNA and VRTX?

Amgen (AMGN) trades on the lowest price-to-earnings ratio (Amgen (AMGN) 27.0x, Moderna (MRNA) -31.3x, Vertex Pharmaceuticals (VRTX) 34.5x). On next year's consensus earnings, Amgen (AMGN) is cheapest (Amgen (AMGN) 20.9x, Vertex Pharmaceuticals (VRTX) 30.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Moderna (MRNA) grew revenue fastest over the trailing twelve months: Amgen (AMGN) +8.2%, Moderna (MRNA) +13.1%, Vertex Pharmaceuticals (VRTX) +10.5%.

Which company is more profitable?

Vertex Pharmaceuticals (VRTX) has the highest net margin (Amgen (AMGN) 24.1%, Moderna (MRNA) -110.5%, Vertex Pharmaceuticals (VRTX) 30.7%). On return on invested capital, Amgen (AMGN) leads (Amgen (AMGN) 15.6%, Moderna (MRNA) -39.6%).

Which stock has performed better?

Over the past year Moderna (MRNA) returned the most: Amgen (AMGN) +38.6%, Moderna (MRNA) +794.9%, Vertex Pharmaceuticals (VRTX) +24.0%. Over five years, Vertex Pharmaceuticals (VRTX) compounded fastest (Amgen (AMGN) +17.1%/yr, Moderna (MRNA) -0.7%/yr, Vertex Pharmaceuticals (VRTX) +23.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Amgen (AMGN) 0.02%, Moderna (MRNA) 0.00%, Vertex Pharmaceuticals (VRTX) 0.00%. Moderna (MRNA) and Vertex Pharmaceuticals (VRTX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Amgen (AMGN) has been the steadiest (Amgen (AMGN) 28.8%, Moderna (MRNA) 130.6%, Vertex Pharmaceuticals (VRTX) 29.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMGN, MRNA and VRTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amgen (AMGN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.